Sigma Planning Corp’s Vertex Pharmaceuticals VRTX Stock Holding History

Sigma Planning Corp’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.88M	Buy	3,609 +2,576	+249%	+$1.32M	0.05%	371
2026 Q2	$513K	Sell	1,033 -29	-3%	-$12.9K	0.01%	905
2026 Q1	$474K	Sell	1,062 -624	-37%	-$291K	0.01%	858
2025 Q4	$764K	Buy	1,686 +54	+3%	+$23.3K	0.02%	629
2025 Q3	$639K	Sell	1,632 -648	-28%	-$271K	0.02%	712
2025 Q2	$1.01M	Sell	2,280 -34	-1%	-$15.7K	0.03%	496
2025 Q1	$1.12M	Sell	2,314 -17	-0.7%	-$7.92K	0.04%	457
2024 Q4	$939K	Sell	2,331 -415	-15%	-$192K	0.03%	510
2024 Q3	$1.28M	Sell	2,746 -261	-9%	-$125K	0.04%	416
2024 Q2	$1.41M	Buy	3,007 +14	+0.5%	+$6.08K	0.04%	375
2024 Q1	$1.25M	Buy	2,993 +1,212	+68%	+$512K	0.04%	436
2023 Q4	$724K	Sell	1,781 -1,061	-37%	-$392K	0.06%	339
2023 Q3	$988K	Buy	2,842 +80	+3%	+$28K	0.04%	471
2023 Q2	$972K	Buy	2,762 +10	+0.4%	+$3.37K	0.03%	464
2023 Q1	$867K	Sell	2,752 -412	-13%	-$124K	0.03%	569
2022 Q4	$914K	Buy	3,164 +44	+1%	+$13.4K	0.03%	519
2022 Q3	$903K	Buy	3,120 +1,082	+53%	+$311K	0.03%	494
2022 Q2	$574K	Buy	2,038 +535	+36%	+$143K	0.02%	700
2022 Q1	$392K	Sell	1,503 -112	-7%	-$26.6K	0.01%	942
2021 Q4	$355K	Sell	1,615 -1,193	-42%	-$232K	0.01%	1000
2021 Q3	$509K	Buy	2,808 +1,201	+75%	+$234K	0.02%	808
2021 Q2	$324K	Buy	1,607 +390	+32%	+$81.6K	0.01%	1042
2021 Q1	$262K	Buy	1,217 +22	+2%	+$4.83K	0.01%	1064
2020 Q4	$282K	Buy	+1,195	New	+$274K	0.01%	934
2020 Q3	–	Sell	-9,006	Closed	-$2.62M	–	1168
2020 Q2	$2.62M	Buy	+9,006	New	+$2.44M	0.11%	183
2020 Q1	–	Sell	-1,104	Closed	-$242K	–	1116
2019 Q4	$242K	Buy	+1,104	New	+$223K	0.01%	891
2015 Q1	–	Sell	-8,483	Closed	-$1.01M	–	790
2014 Q4	$1.01M	Buy	+8,483	New	+$955K	0.13%	181

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Sigma Planning Corp's VRTX Position: Q3 2026 in Review

Sigma Planning Corp increased its Vertex Pharmaceuticals (VRTX) stake by 249% in Q3 2026, buying an estimated $1.32M and bringing the position to 3,609 shares worth $1.88M. The position accounts for 0.05% of the portfolio, ranked #371.

Sigma Planning Corp first reported a position in VRTX in Q4 2014 and has held it in 27 quarters since. The position peaked at $2.62M in Q2 2020. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Sigma Planning Corp held 3,609 shares of Vertex Pharmaceuticals worth $1.88M as of Q3 2026.
Sigma Planning Corp bought 2,576 Vertex Pharmaceuticals shares in Q3 2026, an estimated $1.32M.
Vertex Pharmaceuticals made up 0.05% of Sigma Planning Corp's portfolio in Q3 2026, its #371 holding.
Sigma Planning Corp first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 27 quarters since.
Sigma Planning Corp's Vertex Pharmaceuticals position peaked at $2.62M in Q2 2020.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Sigma Planning Corp's 13F filing for Q3 2026, filed 23 Oct 2026.